Spruce Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 29
- Market Cap
- $19.7M
- Website
- http://www.sprucebio.com
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 27
- Registration Number
- NCT05370521
- Locations
- 🇺🇸
Spruce Study Site, Morgantown, West Virginia, United States
A Phase 2 Study to Evaluate the Safety, Efficacy and PK of Tildacerfont in Children with CAH
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 70
- Registration Number
- NCT05128942
- Locations
- 🇺🇸
Spruce Study Site, Richmond, Virginia, United States
A Ph2b to Evaluate Tildacerfont in the Reduction of Glucocorticoid Steroid Doses in Adult CAH
Phase 2
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 90
- Registration Number
- NCT04544410
- Locations
- 🇬🇧
Spruce Study Site, Birmingham, United Kingdom
🇺🇸Spruce Biosciences Clinical Site, Ann Arbor, Michigan, United States
A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
- First Posted Date
- 2020-07-07
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 96
- Registration Number
- NCT04457336
- Locations
- 🇺🇸
Spruce Clinical Site, Fort Worth, Texas, United States
🇬🇧Spruce Study Site, Birmingham, United Kingdom
🇦🇺Spruce study site, Brisbane, Australia
Study to Evaluate the Safety and Efficacy of SPR001 in Subjects With Classic Congenital Adrenal Hyperplasia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 11
- Registration Number
- NCT03687242
- Locations
- 🇺🇸
Spruce Biosciences Clinical Site, Philadelphia, Pennsylvania, United States
Study of SPR001 in Adults With Classic Congenital Adrenal Hyperplasia
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2017-08-22
- Last Posted Date
- 2019-06-26
- Lead Sponsor
- Spruce Biosciences
- Target Recruit Count
- 26
- Registration Number
- NCT03257462
- Locations
- 🇺🇸
Spruce Biosciences Clinical Site, Philadelphia, Pennsylvania, United States
© Copyright 2024. All Rights Reserved by MedPath